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ARTICLE
Macrophage hypoxia signaling regulates cardiac
ﬁbrosis via Oncostatin M
Hajime Abe1,2, Norihiko Takeda1,3, Takayuki Isagawa4, Hiroaki Semba1,5, Satoshi Nishimura3,6,
Masaki Suimye Morioka7, Yu Nakagama 8, Tatsuyuki Sato 1, Katsura Soma1, Katsuhiro Koyama1,
Masaki Wake1, Manami Katoh1, Masataka Asagiri9, Michael L. Neugent10, Jung-whan Kim10,
Christian Stockmann11,12, Tomo Yonezawa13, Ryo Inuzuka8, Yasushi Hirota 14, Koji Maemura4,
Takeshi Yamashita 5, Kinya Otsu2, Ichiro Manabe15, Ryozo Nagai16 & Issei Komuro1
The ﬁbrogenic response in tissue-resident ﬁbroblasts is determined by the balance between
activation and repression signals from the tissue microenvironment. While the molecular
pathways by which transforming growth factor-1 (TGF-β1) activates pro-ﬁbrogenic
mechanisms have been extensively studied and are recognized critical during ﬁbrosis
development, the factors regulating TGF-β1 signaling are poorly understood. Here we show
that macrophage hypoxia signaling suppresses excessive ﬁbrosis in a heart via oncostatin-m
(OSM) secretion. During cardiac remodeling, Ly6Chi monocytes/macrophages accumulate in
hypoxic areas through a hypoxia-inducible factor (HIF)-1α dependent manner and suppresses
cardiac ﬁbroblast activation. As an underlying molecular mechanism, we identify OSM, part
of the interleukin 6 cytokine family, as a HIF-1α target gene, which directly inhibits the TGF-β1
mediated activation of cardiac ﬁbroblasts through extracellular signal-regulated kinase 1/2-
dependent phosphorylation of the SMAD linker region. These results demonstrate that
macrophage hypoxia signaling regulates ﬁbroblast activation through OSM secretion in vivo.
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Cardiac remodeling occurs after myocardial infarction orpressure overload. During the remodeling processes,activated ﬁbroblasts (myoﬁbroblasts) cause cardiac ﬁbrosis
development in the infarcted areas of the myocardium in order to
support the structure of the heart1–3. Cardiac ﬁbrosis also occurs
in pressure overload-induced cardiac remodeling, leading to the
development of heart failure with preserved ejection fraction
(HFpEF), a form of congestive heart failure in which the fraction
of blood ejected from the left ventricle is within normal thresh-
olds (>50%)4. In both myocardial infarction and pressure
overload-induced cardiac ﬁbrosis, the extent of interstitial ﬁbrosis
correlates with mortality and major cardiovascular adverse event
rates in heart failure patients5–8. Therefore, elucidation of the
molecular processes by which ﬁbroblasts are activated or deacti-
vated is critically important for the development of therapeutic
approaches in the management of cardiac ﬁbrosis.
During ﬁbrogenesis, several subsets of monocytes/macrophages
(MΦ) are recruited to the heart including both pro-inﬂammatory
(Ly6Chi) and anti-inﬂammatory (Ly6Clo) MΦ9 and play a critical
role in tissue remodeling. The extent of inﬂammation sig-
niﬁcantly correlates to the severity of heart failure10–12. Notably,
local oxygen concentration within inﬂamed areas tends to be
decreased, leading to tissue hypoxia13,14. The transcription factor,
hypoxia-inducible factor (HIF)-1α and HIF-2α are stabilized
under hypoxic conditions. In its stable form, HIF-αs induce target
gene expression through their binding to the hypoxia response
elements (HREs) of target genes15–23. We previously showed that
HIF-1α and HIF-2α are highly expressed in pro-inﬂammatory
and anti-inﬂammatory MΦ, respectively24. During cell migration,
cytosolic ATP is rapidly consumed at the ﬁlopodia or lamelli-
podia. Recently, we revealed that HIF-1α mediated glycolytic
reprogramming plays a key role for MΦ to mobilize towards the
hypoxic tissue25. Pyruvate kinase, muscle type, a glycolytic
enzyme capable of producing ATP, localizes in the ﬁlopodia and
lamellipodia, which may account for the beneﬁcial roles of gly-
colytic metabolism in MΦ migration.
The roles of MΦ, however, in tissue ﬁbrosis have not been fully
elucidated9,26. The current study examine the roles of MΦ in
cardiac ﬁbrosis using murine model of cardiac remodeling. The
results demonstrate that Ly6Chi MΦ accumulate in hypoxic areas
and suppress excessive ﬁbrosis in cardiac tissue by secreting a
cytokine Oncostatin-M (OSM) in vivo.
Results
Ly6Chi/lo MΦ accumulate to the heart after TAC procedure.
TAC is a commonly used experimental model for inducing car-
diac ﬁbrosis. To identify the population of cardiac inﬂammatory
cells which accumulates in the heart tissue, we performed
ﬂuorescence-activated cell sorting (FACS) analysis of cardiac
tissues after administering the TAC operation. In this study, we
deﬁned cardiac MΦ as CD11b+, F4/80+, Ly6G−mononuclear
cells27. Cardiac MΦ acutely, but transiently accumulate in the
heart after TAC (Fig. 1a). Ly6C is known as a surface marker for
deﬁning cardiac MΦ subpopulations28. We next isolated two MΦ
subsets including Ly6Chi MΦ and Ly6Clo MΦ (Supplementary
Fig. 1)9,29. Cardiac Ly6Chi MΦ highly express Interleukin 1 beta
(Il1b) and C-C chemokine receptor type 2 (Ccr2), whereas Ly6Clo
MΦ express Mannose receptor, C type 1 (Mrc1) and Arginase 1
(Arg1) (Supplementary Fig. 2). Most of the cells recruited at day 3
were Ly6Chi MΦ, and day 7 or 14 were Ly6Clo MΦ (Fig. 1b).
Ly6Chi MΦ accumulate in hypoxic regions. Chemokine (C-C
motif) ligand 2 (Ccl2) and chemokine (C-X3-C motif) ligand 1
are chemokines, which have a potential to recruit Ly6Chi and
Ly6Clo MΦ, respectively9. While the recruited MΦ presumably
modulates cardiac ﬁbrosis, its migration process is signiﬁcantly
inﬂuenced by tissue oxygenation14,25. To test whether hypoxic
areas develop during cardiac remodeling, we performed in vivo
two photon microscopic analyses using a phosphorescent hypoxia
probe, LOX-1. Striking augmentation of LOX-1 signal was
observed at 3 days after TAC operation, reﬂecting tissue hypoxia
(Fig. 1c). We used another hypoxia probe, pimonidazole (Pimo),
to further examine the oxygenation status of cardiac tissues30.
Pimo staining was visualized in the whole area of the heart at
3 days after TAC (Supplementary Fig. 3). To clarify the molecular
link between mechanical stress and tissue hypoxia, we isolated
primary cardiomyocytes and measured the oxygen consumption
rate (OCR) using ﬂux analyzer (XF24, Agilent Technologies,
USA). OCR of the cardiomyocytes was increased at day 3 after
TAC operation (Supplementary Fig. 4). These results indicate a
hypothesis that elevated oxygen demand in cardiomyocytes
underlies the occurrence of tissue hypoxia in pressure
overloaded heart.
We next measured Pimo signals in cardiac MΦ. Ly6Chi MΦ
displayed a higher Pimo signal intensity than Ly6Clo MΦ,
suggesting that Ly6Chi MΦ indeed accumulate in hypoxic areas
in vivo (Fig. 1d). To test the roles of HIF-1α signaling in cardiac
MΦ distribution, we generated myeloid-speciﬁc HIF-1α knockout
mice (HIF-1αﬂox/ﬂox; LysM-cre+/−, mHIF-1α CKO)31,32. The
deletion efﬁciency of the HIF-1α gene at the mRNA level was
more than 65% in both Ly6Chi MΦ and Ly6Clo MΦ in the heart
(Supplementary Fig. 5). The baseline cardiac function was
unaltered in mHIF-1α CKO mice compared with cre negative
controls (Supplementary Fig. 6). We next performed the TAC
procedure in mHIF-1α CKO mice. The results showed that the
cardiac accumulation of Ly6Chi MΦ at day 3 was strikingly
decreased in mHIF-1α CKO, whereas that of Ly6Clo MΦ was not
affected (Fig. 1e). These results show that HIF-1α signaling plays
an integral role in the recruitment of Ly6Chi MΦ to the hypoxic
area of the heart, but not of Ly6Clo MΦ.
Cardiac ﬁbrosis develops in HIF-1α knockout mice. We next
measured the ﬁbrotic area and found that it was signiﬁcantly
larger in mHIF-1α CKO mice compared with the controls
(Fig. 2a). Whereas the number of CD31-positive cells remained
unchanged, the number of alpha-smooth muscle actin (αSMA)-
positive myoﬁbroblasts was increased in mHIF-1α CKO mice
(Fig. 2b, Supplementary Fig. 7). The number of TdT-mediated
dUTP nick end labeling (TUNEL)-positive cells was not
increased in mHIF-1α CKO mice (Supplementary Fig. 8),
indicating that loss of myeloid cell-speciﬁc HIF-1α did not
affect cardiomyocyte survival in vivo. While these results
indicate the anti-ﬁbrotic activity of Ly6Chi MΦ, the roles of
Ly6Clo MΦ in cardiac ﬁbrosis still remained unclear. Therefore,
we injected clodronate liposomes intraperitoneally to further
deplete Ly6Clo MΦ in mHIF-1α CKO mice. Injection of clo-
dronate liposomes did not affect the extent of cardiac ﬁbrosis
(Supplementary Fig. 9). These results suggest that Ly6Chi MΦ
hypoxia signaling elicits the major role in regulating cardiac
ﬁbrosis in vivo. In addition, mHIF-1α CKO mice had sig-
niﬁcantly decreased left ventricular ejection fractions along
with increased heart weights (Fig. 2c, d and Supplementary
Figs. 10, 11) as well as markedly decreased survival after the
TAC procedure (Fig. 2e). These data indicate that MΦ hypoxia
signaling has a cardio-protective role in TAC model. To further
examine the roles of MΦ HIF-1α signaling in the development
of replacement ﬁbrosis, we performed myocardial infarction
model using mHIF-1α CKO mice. Fibrotic area in myocardial
infarction model was signiﬁcantly larger in mHIF-1α CKO mice
compared with controls (Supplementary Fig. 12).
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MΦ derived Oncostatin M suppresses ﬁbroblast activation. To
elucidate the molecular mechanisms by which hypoxic MΦ reg-
ulate ﬁbroblast activation, we established an in vitro assay system
using C3H/10T1/2 cells, a mouse embryo ﬁbroblast cell line, and
thioglycollate-elicited peritoneal macrophages (TEPMs). TGF-β1
induces αSMA mRNA expression in C3H/10T1/2 cells, which is
known as an activation marker of ﬁbroblasts. While the culture
supernatant of TEPMs kept under normoxic conditions did not
alter the expression of αSMA mRNA, the culture supernatant of
TEPMs kept under hypoxic conditions signiﬁcantly suppressed
αSMA mRNA expression (Fig. 3a). Based on this ﬁnding, we
hypothesized that hypoxia stimulates the secretion of some
unknown factors in TEPMs, which suppress ﬁbroblast activation.
To identify the hypoxia-stimulated secretion factors that have
anti-ﬁbrotic potential, we isolated primary TEPMs from hemato-
poietic/endothelial-speciﬁc HIF-1α knockout mice (HIF-1αﬂox/ﬂox;
Tie2-cre+/− mice; HIF-1α KO) or cre negative littermate controls.
Subsequently, we performed transcriptome analysis and searched
for any secretory factors that are highly expressed in hypoxic
conditions through a HIF-1α-dependent manner (Fig. 3b, left).
This unbiased approach revealed 11 secretory factors, including
Connective tissue growth factor (Ctgf), Chemokine (C-X-C motif)
ligand 2 (Cxcl2), Cxcl3, Leukemia inhibitory factor (Lif) and Osm
(Fig. 3b, right). To test their effects on ﬁbroblast activation, we
treated C3H/10T1/2 cells with 10 of the identiﬁed secretory factors
those we could obtain on a commercial basis, and tested their
effects on ﬁbroblast activation. Through this approach, we
discovered that OSM, a member of the IL6–type family of
cytokines, signiﬁcantly suppressed αSMA mRNA expression in
C3H/10T1/2 cells (Fig. 3c, Supplementary Fig. 13). OSM also
suppressed the activation of isolated mouse primary cardiac
ﬁbroblasts (Fig. 3d). We further tested the expression of OSM in
the heart and identiﬁed that OSM is highly expressed in murine
cardiac MΦ (Fig. 3e).
OSM is induced in hypoxia through a HIF-1α dependent
manner. We cultured wild type TEPMs or bone marrow derived
macrophages under 1% oxygen concentration and found that the
Osm mRNA levels were signiﬁcantly elevated under hypoxia
(Fig. 4a, Supplementary Fig. 14). Hypoxia elicited elevation of
Osm gene expression was signiﬁcantly suppressed in HIF-1α KO
TEPMs, indicating that the abundance of Osm mRNA is
increased in a HIF-1α-dependent manner. To examine the
molecular mechanisms by which HIF-1α induces Osm gene
expression, we next performed chromatin immunoprecipitation
(ChIP) assay with anti-HIF-1α antibody. The results showed the
direct binding of HIF-1α to the HRE sequence 4 kb upstream of
the Osm transcription start site (Fig. 4b). To evaluate the roles of
Osm HRE sequence in its transcriptional activation, we generated
a reporter construct containing the HRE sequence of Osm. Co-
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Fig. 1 Cardiac inﬁltration of MΦ after TAC operation. a Data represent the cardiac inﬁltration of MΦ (CD11b+, F4/80+, Ly6G− mononuclear cells) after
TAC operation. b Data represent the cardiac inﬁltration of Ly6Chi MΦ and Ly6Clo MΦ after TAC operation. *Ly6Chi MΦ. †Ly6Clo MΦ. The Kruskal–Wallis
test was used for the statistical analysis. (Figure a, b; n= 5 at day 0, 3, 7, 14, and 28). c Hypoxic area was visualized in TAC operated mice (3 days after
TAC) using LOX-1 (red). Vasculatures and nucleus were labeled with isolectin (green) and Hoechst 33342 (blue) (left). Scale bar= 50 μm. LOX-1 signal
intensity was calculated in sham or TAC operated mouse (right). (ROI number 180, sham and TAC operated mouse, respectively). d MΦ after TAC
operation were stained with Pimonidazole (Pimo). The population of Pimo positive cells in Ly6Chi MΦ (day 3, n= 5) and Ly6Clo MΦ (day 7, n= 5) are
shown. e Cardiac inﬁltration of Ly6Chi MΦ and Ly6Clo MΦ in myeloid-speciﬁc HIF-1α conditional knockout mice (mHIF-1α CKO: HIF-1αﬂox/ﬂox; LysM-cre+/−)
were analyzed 3 or 7 days after TAC operation. Cre negative littermates were used as a control (cont). Day 3, cont (n= 6) and mHIF-1α CKO (n= 4). Day
7, cont (n= 3) and mHIF-1α CKO (n= 4). The Mann–Whitney U test was used to compare differences (c, d, e). Error bar represents the standard
deviation. n.s. not statistically signiﬁcant. * or †, p < 0.05
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transfection of HIF-1α and aryl hydrocarbon receptor nuclear
translocator signiﬁcantly enhanced the luciferase activity of the
reporter construct containing Osm HRE sequences (Supplemen-
tary Fig. 15). Together, these results demonstrate that Osm
expression is directly induced in hypoxia through a HIF-1α-
dependent manner.
OSM inhibits SMAD signaling pathway. We further investi-
gated the molecular processes by which OSM decreases αSMA
mRNA expression level in C3H/10T1/2 cells and primary cardiac
ﬁbroblasts. While OSM suppressed TGF-β1 mediated augmen-
tation of αSMA mRNA expression, IL6 did not affect its abun-
dance (Fig. 5a, Supplementary Fig. 16), suggesting that the anti-
ﬁbrotic effect is speciﬁc to OSM and not a general feature of the
IL6 cytokine family. TGF-β1 signaling is mainly mediated
through a canonical SMAD signaling pathway. It has been shown
that extracellular signal-regulated kinase 1/2 (ERK1/2) mediated
phosphorylation of the SMAD linker region suppresses its nuclear
translocation33–37. In this study, we found that OSM activates
ERK signaling in C3H/10T1/2 cells (Fig. 5b). Furthermore, OSM
elicits the phosphorylation of SMAD2 linker region (Ser245/250/
255), which was abolished by U0126, a selective MEK1/2 inhi-
bitor. Notably, IL6 does not affect the phosphorylation of SMAD2
linker region. Next we extracted nuclear fractions and examined
SMAD2 C-terminal (Ser465/467) phosphorylation, an activation
marker of SMAD2 signaling. OSM signiﬁcantly suppressed the
accumulation of activated SMAD2 in the nucleus (Fig. 5c).
Consistent with our hypothesis, U0126 attenuated the inhibitory
effect of OSM on αSMA gene expression in C3H/10T1/2 cells and
primary cardiac ﬁbroblasts (Fig. 5d, Supplementary Fig. 17).
These results indicate that OSM exerts its anti-ﬁbrotic effect
partly through ERK1/2-mediated phosphorylation of the SMAD2
linker region.
OSM suppresses cardiac ﬁbrosis in vivo. It should be noted that
OSM suppressed ﬁbroblast activation, whereas IL6 did not. While
OSM and IL6 share gp130 as a co-receptor for the signaling,
murine OSM receptor (OSMR) is speciﬁcally activated by OSM
but not IL6. To test the effect of OSM on cardiac ﬁbroblast
in vivo, we generated ﬁbroblast-speciﬁc Osmr knockout mice
(OSMRﬂox/ﬂox; Col1a1-creERT, fOSMR CKO)38. The extent of
baseline cardiac ﬁbrosis or heart weight remain unchanged in
fOSMR CKO mice (Supplementary Fig. 18). We next performed
murine TAC operation in fOSMR CKO mice and cre-negative
littermates or tamoxifen untreated mice as controls. Cardiac
ﬁbrosis was more prominent in fOSMR CKO mice than controls
(Fig. 6a). To further determine the roles of OSM in vivo, we
injected OSM neutralizing antibody and measured the area of
cardiac ﬁbrosis in the murine TAC model. The results showed
that inhibition of OSM signiﬁcantly augments the development of
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cardiac ﬁbrosis (Fig. 6b). Collectively, these data suggest that
OSM directly suppresses the activation of cardiac ﬁbroblasts both
in vitro and in vivo. Finally, we examined the expression of OSM
in human heart specimens, which were obtained from heart
failure patients. Notably, the number of OSM-positive cells in
human heart specimen inversely correlated with the area of car-
diac ﬁbrosis (Fig. 6c, Supplementary Fig. 19), which is consistent
with the anti-ﬁbrotic function of OSM.
Discussion
Cardiac ﬁbroblasts are activated not only in myocardial infarc-
tion, but also in pressure-overload-induced cardiac hypertrophy.
Despite the fact that MΦ could suppress cardiac ﬁbrosis9, its
regulatory signals have not been fully elucidated. Here, we used a
hypoxia probe in vivo, and demonstrated that tissue hypoxia
develops in pressure-overload-induced cardiac remodeling. We
further discovered that hypoxic MΦ, but not normoxic MΦ,
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Fig. 3 Oncostatin M from hypoxic MΦ inhibits ﬁbroblast activation. a Supernatants were collected from thioglycollate-elicited peritoneal macrophages
(TEPMs) under normoxic or hypoxic condition. After pretreatment with the supernatants, C3H/10T1/2 cells were stimulated with TGF-β1 (2.5 ng per ml,
12 h) and the relative expression of αSMA mRNA was calculated (right). The one-way ANOVA and Dunnett’s multiple comparisons test were used for the
statistical analysis (F (2, 6)= 6.019). b We performed transcriptome analysis in isolated primary TEPMs from hematopoietic/endothelial-speciﬁc HIF-1α
conditional knockout mice (HIF-1αﬂox/ﬂox; Tie2-cre+/− mice; HIF-1α KO) or cre negative littermate control. Flow chart shows the strategy to identify
hypoxia-inducible secretory factors (left). Table illustrates the identiﬁed 11 hypoxia-inducible secretory factors (right). c The effect of each hypoxic
inducible secretory factor in ﬁbroblasts activation was examined (20 ng per ml for CTGF, CXCL2, CXCL3, LIF and 10 ng per ml for OSM). Thirty minutes
after pretreatment with hypoxia-inducible secretory factors, C3H/10T1/2 cells were stimulated with TGF-β1 (2.5 ng per ml, 12 h) and the relative
expression of αSMA mRNA was calculated. The one-way ANOVA and Dunnett’s multiple comparisons test were used for the statistical analysis (F (5, 12)
= 68.07). d The effect of oncostatin M (OSM) (10 ng per ml) in primary cardiac ﬁbroblasts activation was examined. Thirty minutes after pretreatment
with OSM (10 ng per ml, 12 h), C3H/10T1/2 cells were stimulated with TGF-β1 (2.5 ng per ml, 12 h) and the relative expression of αSMA mRNA was
calculated. Two-tailed t-test with Welch’s correction was used for the statistical analysis (t= 10.89, df= 2.208). Data show the mean and the standard
deviation (error bar) of technical triplicates from a representative experiment. e Immunohistological staining were performed using cardiac tissues from
TAC operated mice (day 3). OSM (left), CD11b (right). Scale bar= 50 μm. *p < 0.05
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the statistical analysis (F (2, 12)= 94.66). *p < 0.05 vs cont. b HIF-1α binding to the promoter of Osm gene was studied by chromatin immunoprecipitation
coupled to detection by quantitative PCR. Primer set 1 and 2 were designed to detect the promoter legion (−500 and −170 bp) of Pgk1 gene. Primer set 3
and 4 were designed to detect the hypoxia response element (HRE, −4 kb) of Osm gene. Data show the mean and the standard deviation (effort bar) of
technical triplicates from a representative experiment. Quantitative PCR analysis were repeated at least three independent experiments. Two-tailed t-test
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suppresses ﬁbroblast activation through the secretion of OSM.
While both OSM and IL6 transduce their signals through gp130,
OSMR speciﬁcally interact with src homology 2 domain-
containing transforming protein C1 (SHC1)39. This seems to
account for the OSM mediated activation of ERK signaling,
contributing to its anti-ﬁbrotic properties. OSM was also shown
to have a protective effect in ischemic myocardium40,41, thus
Ly6Chi MΦ-derived OSM exerts a cardio-protective effect on
both cardiomyocytes and cardiac ﬁbroblasts. Our results
demonstrate a functional link between sterile inﬂammation and
cardiac ﬁbrosis.
In myocardial infarction model, Ly6Chi and Ly6Clo MΦ
sequentially accumulate in the heart9. It has also been shown that
CCL2 or Regenerating islet-derived 3β (Reg3β) has a strong
potential to recruit Ly6Chi MΦ to the damaged heart42. In our
model, the expression of Ccl2, but not Reg3β is highly induced at
day 3 after TAC (Supplementary Fig. 20). While it is uncertain
whether Ly6Chi and Ly6Clo MΦ give rise to distinct macrophage
subsets in the heart, the results of our study are consistent with
the ﬁnding that Ly6Chi MΦ are recruited to the damaged heart
through the CCL2-CCR2 axis9.
The results of this study have revealed an anti-ﬁbrotic effect of
OSM (Supplementary Fig. 21). We still need to be careful in using
OSM or an OSMR agonist for the management of cardiac ﬁbrosis,
since it may have a potential to drive intestinal inﬂammation43.
Therefore, selective delivery of OSM to the heart such as coronary
artery injection seems to be necessary to manage cardiac ﬁbrosis
effectively. It should also be noted that the ﬁbroblast activation
processes in TAC model may be quite different from that in
myocardial infarction. Further investigation, therefore, will help
to understand the context dependent activation processes of
cardiac ﬁbrosis in more detail.
Methods
Mice and surgical procedures. All animal experiments were approved by the
University of Tokyo Ethics Committee for Animal Experiments or King’s College
London Ethical Review Process Committee and UK Home Ofﬁce (Project License
No. PPL70/7260). The procedures are strictly adhered to the guidelines for animal
experiments of the University of Tokyo or the Guidance on the Operation of the
Animals (Scientiﬁc Procedures) Act, 1986 (UK Home Ofﬁce). C57BL/6 mice were
purchased from Crea Japan (Tokyo, Japan) or Envigo (Blackthorn, UK). B6.129-
Hif1atm3Rsjo/J (HIF-1αﬂox/fox) mice, B6;129-Osmrtm1.1Nat/J (OSMRﬂox/ﬂox) mice,
B6.129P2-Lyz2tm1(cre)Ifo/J (LysM-cre) mice, B6.Cg-Tg(Tek-cre)12Flv/J (Tie2-cre)
mice and B6.Cg-Tg(Col1a1-cre/ERT2)1Crm/J (Col1a1-creERT) mice were pur-
chased from The Jackson Laboratory (Bar Harbor, Maine, USA). HIF-1αﬂox/fox,
LysM-Cre and Tie2-cre mice were backcrossed to C57BL/6 background. Mice were
housed in a speciﬁc pathogen-free facility with a 12-h light/12-h dark cycle.
Tamoxifen (1 mg) (Sigma–Aldrich, St-Louis, USA) was injected intraperitoneally
for 7 days to induce cre-mediated recombination in Col1a1-creERT mice. Corn oil
was administered in control groups. Seven days following cessation of tamoxifen
animals were subjected to TAC procedure. Male mice 7–12 weeks of age were used
for TAC operation. TAC operation was performed as follows, a 27-gauge needle
was placed next to the aortic arch, the suture was tied ﬁrmly two times around the
27-gauge needle and the aorta, and the needle was removed34. Sham operated mice
underwent the same procedure but without constriction. Mice were closely
observed and euthanized quickly, at a humane end point (no locomotion or body
weight loss exceeding 20% of the initial body weight).
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10859-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2824 | https://doi.org/10.1038/s41467-019-10859-w |www.nature.com/naturecommunications 7
Cells, reagents, recombinant proteins, and antibodies. Mesenchymal stem cell
line C3H10T1/2 cells were purchased from American Type Culture Collection.
C3H10T1/2 cells were grown in DMEM (Dulbecco’s Modiﬁed Eagle Medium)
medium containing 10% fetal bovine serum (HyClone, GE Healthcare Japan,
Tokyo, Japan) in a 37 °C incubator (5% CO2). TEPMs were collected from the
peritoneal cavity 4 days after the intraperitoneal injection of 3% thioglycollate
solution (Fluka, Sigma–Aldrich, St Louis, MO, USA) using female mice. TEPMs
were grown in RPMI1640 (GIBCO, Life technologies, Carlsbad, CA, USA) medium
containing 10% fetal bovine serum (HyClone) in a 37 °C incubator (5% CO2).
Adult male mice at the age of 6–8 weeks were used for the isolation and cultivation
of cardiac ﬁbroblasts44. Two or three hearts of ventricles were isolated and quickly
minced into small pieces. After incubation at 37 °C for 30 min with DMEM con-
taining Liberase TH (25 μg per ml, Sigma–Aldrich) and elastase (1.2 U per ml,
Worthington Biochemical Corporation, Freehold, NJ, USA), the cell suspensions
were pelleted and washed with PBS(-). All cell suspensions were plated on a
collagen-coated dish (Cosmo Bio, Tokyo, Japan) in DMEM supplemented with
10% of fetal bovine serum. After overnight incubation, nonadherent cells were
removed, and adherent cells were cultivated. Primary ﬁbroblasts at passage 1 or 2
were used for experiments.
Recombinant mouse OSM (catalog no. 495-MO-025), mouse IL6 (catalog no.
406-ML-005), and human TGF-β1 (catalog no. 240-B-010) were all purchased
from R&D Systems (Minneapolis, MN, USA). Recombinant mouse CTGF (catalog
no. RPA010MU01) was purchased from Cloud-Clone Corp. (Katy, TX, USA).
Recombinant mouse CXCL2 (catalog no. 582502), mouse LIF (catalog no 554002)
and mouse CXCL3 (catalog no. 590802) were purchased from Bio Legend (San
Diego, CA, USA). All recombinant proteins used in cell culture were diluted in
0.5% BSA solution (Sigma, catalog no. A8806-1G).
APC-CD11b (M1/70) (diluted 1:1000, 17-0112-82; eBioscience, PE-F4/80
(BM8) (diluted 1:1000, 123110; BioLegend, FITC-Ly6C (HK1.4) (diluted 1:1000,
128006; BioLegend, Paciﬁc Blue-Ly6G (1A8) (diluted 1:1000, 127612; BioLegend)
were used for the FACS analysis. Mouse OSM antibody (AF-495-NA; R&D) or
normal Goat IgG control (AB-108-C; R&D) was used as a neutralizing antibody or
control IgG in vivo. Human OSM antibody (diluted 1:500, NBP1-87768; R&D) and
mouse OSM antibody (diluted 1:500, bs-5095R; BIS) were used for the OSM
staining in human and mouse heart tissues respectively. Mouse CD11b antibody
(diluted 1:2000, ab133357; Abcam, Cambridge, UK) was used for the CD11b
staining in mouse heart tissues.
Exposure of cell cultures to hypoxia (1% O2) was performed in the hypoxic
workstation In Vivo2 500 (Ruskinn Technology, Bridgend, UK). The serum free
culture medium of TEPMs was changed 12 h after hypoxic exposure. Follow which,
TEPMs were exposed to hypoxia for 12 h, and their supernatant was collected and
used in the analysis of ﬁbroblast activation.
Preparation of clodronate liposomes. Clodronate liposomes were generated as
follows45. After 8 mg cholesterol was dissolved in 10 ml chloroform, 0.86 ml of
phosphatidylcholine solution (containing 86 mg phosphatidylcholine) was added.
The chloroform phase was removed by low vacuum rotation (1.257 × g) evapora-
tion. The phospholipid ﬁlm was dispersed in 10 ml of aqueous solution containing
0.6 M clodronate by gentle rotation at room temperature. The milky white sus-
pension was kept at room temperature for 2 h under nitrogen gas. The suspension
was sonicated in a waterbath sonicator for 3 min and kept overnight at 4 °C. After
centrifugation (10,000 × g for 15 min), the solution under the white band of lipo-
somes was removed using a Pasteur pipette. The clodronate liposomes are washed
three times using sterilized PBS (Centrifugation at 25,000 × g for 30 min). Finally,
the pellet was resuspended in 4 ml sterilized PBS.
Flow cytometry. All ﬂow cytometric analyses and sorting were performed using
FACS aria II (BD) and FlowJo software (Tree Star). To isolate cells from hearts,
whole heart was cut into small pieces in DMEM (containing 10% fetal bovine
serum). The collected tissue was incubated for 2 h with collagenase type I (1 mg per
ml, Worthington Biochemical Corporation) and elastase (0.74 U per ml, Wor-
thington Biochemical Corporation) in Hanks’ buffered saline solution (HBSS). The
suspension was passed through a 22-gauge needle and washed in ice-cold PBS(−)
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containing 5% fetal bovine serum. After removing any erythrocytes using BD
PharmLyse (BD), the samples were subjected to ﬂow cytometric analysis.
The heart samples were obtained 45 min. after intraperitoneal injection of
pimonidazole (Pimo, 60 mg per kg) (hpi, Burlington, MA, USA). Intracellular
incorporation of Pimo was analyzed by multicolor FACS with a ﬂuorescein (FITC)-
conjugated anti-Pimo antibody (diluted 1:1000, hpi)
Intravital visualization of hypoxic signals in heart. Hypoxic state is visualized
using two photon microscope and phosphorescence probe, LOX-1 (Scivax Life
Sciences, Tokyo, Japan)46. Anesthesized and mechanically-ventilated mice were
administrated with Hoechst 33342 (10 mg per kg, Invitrogen (Thermoﬁsher), blue),
ﬂuorescein labeled Griffonia Simplicifolia Lectin I (GSL I) isolectin B4 (green,
Vector laboratories, FL-1201, 50 μg for each mouse), and LOX-1 hypoxic probes
(100 μg for each mouse, red). Imaging of living heart was performed by two photon
microscope (Nikon-A1RMP, Nikon), femtosecond infrared lasers (Chameleon
Vision-II, Coherent), and ×40 water-immersion objective lens (NA1.15, Nikon).
Signal intensity for LOX-1 was automatically quantiﬁed and statistically analyzed
by NIS-elements software (Nikon).
RNA isolation and quantitative RT-PCR. For gene expression analysis, total RNA
was puriﬁed from cultured cells using RNeasy kits (Qiagen, Tokyo, Japan)
according to the manufacturer’s instructions. Complementary DNA was synthe-
sized using the SuperScript III First-Strand Synthesis System (Life Technologies).
Quantitative real-time PCR (RT-PCR) analyses were conducted using the Light-
Cycler system (Roche Diagnostic, Tokyo, Japan), with 18S rRNA serving as the
internal control. Primer sequences of the analyzed mouse genes are shown in
Supplementary Table 1.
Western blotting. Cell extracts were separated on TGX FastCast acrylamide Kit,
7.5% (BIO RAD Laboratories Inc.), and then transferred to PVDF membrane
(Millipore, Bedford, MA, USA). After blocking in 5% dry milk in Tris-buffered
saline with Tween 20 (0.1%) (TBS-T), the membrane was incubated with primary
antibodies (1:1000) followed by incubation with horseradish peroxidase-conjugated
secondary antibodies (1:2000). Detection was performed using ECL Prime (GE
Healthcare, Logan, UT, USA) according to the manufacturer’s instructions. The
following antibodies were used: SMAD2 (#5339, Cell Signaling Technology,
Danvers, Ma, USA), Phospho-SMAD2 (Ser245/250/255) (#3104, Cell Signaling
Technology, Danvers, MA, USA), Phospho-SMAD2 (Ser465/467) (#3108, Cell
Signaling Technology, Danvers, MA, USA), Lamin A/C (#2032, Cell Signaling
Technology, Danvers, MA, USA), ERK (#4695, Cell Signaling Technology, Dan-
vers, MA, USA), Phospho-ERK (#4370, Cell Signaling Technology, Danvers, MA,
USA), goat anti-rabbit IgG−HRP (#7074, Cell Signaling Technology, Danvers, MA,
USA). After the exposure to phospho ERK1/2 or phosphor SMAD2 C-terminal
antibody, the same membrane was exposed with anti-ERK or Lamin A/C antibody.
Whole images of western blot images are shown in Supplementary Figs. 22–24.
ChIP assay. TEPMs were cross-linked for 10 min by 1% paraformaldehyde. After
neutralization using 0.2 M glycine solution, TEPMs were collected and suspended
in SDS lysis buffer with cOmplete protease inhibitor cocktail (1873580, Roche).
Samples were subjected to fragmentation using Soniﬁer (Branson, Dansbury, USA).
Sonicated samples were immunoprecipitated with the HIF-1α antibody (NB100-
134, Novus Biologicals). ChIP samples were quantiﬁed with RT-PCR using speciﬁc
primer pairs (Supplementary Table 1).
RNA sequencing (RNA-seq) analysis. TEPMs were isolated from HIF-1α KO or
cre negative littermate controls. We exposed TEPMs to hypoxia (1% O2) or nor-
moxia and collected total RNA at 4 h and 12 h time points, then performed
transcriptome analysis (RNA-seq.). Single-end RNA-seq libraries were prepared
using a TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA). Sequencing runs
were performed on an Illumina Genome Analyzer IIx (Illumina, San Diego, CA,
USA). The reads were aligned to the mm9 mouse genome using TopHat (ver.
2.0.0). Generation of gene expression data, normalization and gene annotation
processes were performed using Genomatix Genome Analyzer (Genomatix,
Munich, Germany). The normalized expression value (NE-value) was calculated as
follow: the number of reads per a gene × 107 per the number of mapped reads in
the genome × gene length.
Identiﬁcation of hypoxia-inducible secretory factors. To identify hypoxia-
inducible secretory factors, we performed procedures as follows. Initially, we
selected the genes with NE-value more than 0.01 in at any time points (Analytic
genes: 11,000 genes). Second, we picked up the genes those maximum NE-vale
were upregulated more than 2-folds in hypoxia (Hypoxia upregulated genes: 866
genes). Third, we selected the genes in which hypoxic induction of their expression
is abrogated in HIF-1α KO TEPMs (HIF-1α dependent genes: 614 genes)). Finally,
genes that have gene ontology (GO) terms of ‘cytokine activity’, ‘chemokine
activity’ or ‘growth factor activity’ were extracted (http://www.geneontology.org/)
(Hypoxia-inducible secretory factors: 11 genes).
Histological studies of mouse and human heart tissues. Written informed
consent was obtained from all participants. The study protocol was approved by
the Ethics Committee of The Cardiovascular Institute (Tokyo, Japan), and strictly
adhered to the ethical regulations. Heart tissues were obtained from heart failure
patients, when they underwent heart surgery or endomyocardial biopsy. The
patients with prior medical history of myocardial infarction were excluded.
Immunohistochemistry were performed in each specimen. Masson trichrome
staining and Sirius Red/ Fast Green staining were performed to calculate peri-
vascular and interstitial ﬁbrotic area.
Statistical analysis. All data are shown as average with SD. Comparison between
two groups was analyzed using unpaired two-tailed t-test with Welch’s correction.
Differences among more than two groups were analyzed using one-way or two-way
ANOVA followed by Dunnett’s multiple comparisons test or Sidak’s multiple
comparison test or Kruskal–Wallis test. P -values of less than 0.05 were considered
to be statistically signiﬁcant. Kaplan–Meyer analysis, followed by a long-rank test,
was used to analyze the survival of mice. Linear regression analysis was used for the
correlation between percent of ﬁbrotic area and the number of OSM-positive cells
in the heart tissues. All statistical analyses were performed using Prism 6 for
Windows (version 6.07, GraphPad, San Diego, CA, USA).
Data availability
All data contained in the manuscript are available from the corresponding author upon
reasonable request. The RNA-seq data of peritoneal macrophages have been deposited in
DDBJ BioProject under accession number DRA008230.
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